Skip to main content

NeoClone Nabs $750K SBIR Grant to Continue Developing Ovarian Cancer Antibody Array

NEW YORK (GenomeWeb News) — NeoClone Biotechnology has received a $750,000 Phase II Small Business Innovation Research grant from the National Institutes of Health to help it continue developing an antibody microarray for ovarian cancer, the company said this week.
 
The funding, administered through the National Cancer Institute, will pay for continued research and new equipment and staff for its Madison, Wis., labs.
 
NeoClone said the antibody array will use its proprietary method for generating monoclonal antibodies to certain ovarian cancer-related targets.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.